Outlook Therapeutics Faces Two Make-or-Break July Deadlines Amid Nasdaq Fight and FDA Priority Review

The stock of Outlook Therapeutics has staged a remarkable recovery, gaining nearly 30% in a single week to close at $1.58. That puts the biotech name comfortably above the Nasdaq’s $1.00 minimum bid threshold for now, but the real test lies in a pair of critical events crammed into the next few weeks. On 16 [...] The post Outlook Therapeutics Faces Two Make-or-Break July Deadlines Amid Nasdaq Fight and FDA Priority Review appeared first on NewsCase .